Adversarial Injection · Lurbinectedin (Zepzelca; PM01183; CAS 497871-47-3; IV powder for reconstitution [MW 783.88 g/mol; molecular formula C41H44ClN3O10; 3.2 mg/vial; IV 3.2 mg/m² Q3W as single agent]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST PM1183-CLASS [TETRAHYDRO-β-CARBOLINE BISALKYLATING MARINE ALKALOID ANALOG OF TRABECTEDIN (ET-743; ECTEINASCIDIN-743) WITH DISTINCT BISALKYLATING MECHANISM AND RNA POL II CDK8/CDK9 TRANSCRIPTION INHIBITION] BISALKYLATING MARINE ALKALOID WITH RNA POLYMERASE II CDK8/CDK9 DISPLACEMENT AND TRANSCRIPTION INHIBITION EVER FDA APPROVED; LURBINECTEDIN vs TRABECTEDIN DISTINCTION: trabectedin (Yondelis; CAS 114899-77-3; NDA 207340 Oct 2015) = MONOALKYLATING marine alkaloid with TC-NER RNAPII trapping [covered in Glyphward attack #692; mechanism class 117]; lurbinectedin = BISALKYLATING marine alkaloid [two electrophilic subunit carbons] with BOTH TC-NER RNAPII trapping AND direct CDK8/CDK9 displacement from active gene promoters; PM1183 FRAMEWORK UNIQUE STRUCTURAL FEATURES vs ET-743: lurbinectedin has a TETRAHYDRO-β-CARBOLINE (THβC) subunit replacing the ET-743 tetrahydroisoquinoline subunit — this THβC subunit is the SECOND ALKYLATING GROUP (bifunctional vs monoalkylating ET-743); different DNA minor groove bis-adduct geometry; SCLC TRANSCRIPTIONAL ADDICTION TARGET: SCLC (small cell lung cancer) is characterized by ASCL1 (achaete-scute homolog 1; neuroendocrine lineage transcription factor; also regulated DLL3) + MYC amplification (~20% SCLC) + constitutive super-enhancer-driven gene expression programs (MYC, MCL1, BCL2, NEUROD1, ATOH1); lurbinectedin selectively depletes RNA Pol II [RPB1 largest subunit; CTD phosphorylation cycle: RNA Pol IIa [CTD-Ser5-P; initiation] → RNA Pol IIo [CTD-Ser2-P; elongation]; CDK7/CDK9 kinases phosphorylate CTD] from transcription start sites (TSS) of SCLC super-enhancer-associated genes; CDK8 (Mediator kinase) + CDK9 (P-TEFb; positive transcription elongation factor b) are displaced from MYC/MCL1 gene promoters by lurbinectedin-induced DNA adducts → RNAPII stalling → TC-NER recruitment → XPG/XPF excision → ubiquitin-mediated proteasomal degradation of stalled RNAPII largest subunit RPB1; SCLC SELECTIVE TOXICITY: lurbinectedin 100-fold more active in SCLC vs other solid tumors at equivalent concentrations) · Attack #706

Lurbinectedin (IV PM1183-Class Bisalkylating Tetrahydro-β-Carboline Marine Alkaloid; Zepzelca; PM01183; CAS 497871-47-3; MW 783.88 g/mol; C41H44ClN3O10; MECHANISM: FIRST PM1183-CLASS [DISTINCT FROM TRABECTEDIN ET-743 CLASS — MONOALKYLATING; ATTACK #692 MECHANISM CLASS 117]: BISALKYLATING [TWO ELECTROPHILIC ALKYLATING CENTERS: (1) C21 tetrahydroisoquinoline subunit A → N2-guanine minor groove adduct [same as ET-743 C21]; (2) UNIQUE PM1183 TETRAHYDRO-β-CARBOLINE (THβC) SUBUNIT C → forms SECOND DNA adduct in adjacent minor groove 3' position → NET RESULT: bifunctional intrastrand bis-adduct (same strand; two adjacent guanine N2-H; minor groove; spans ~4-6 bp); TRANSCRIPTION INHIBITION MECHANISM: lurbinectedin bis-adducts at transcription start sites (TSS) and gene bodies of actively transcribed SCLC super-enhancer genes → stalls elongating RNA Polymerase II (RPB1 CTD-Ser2-P form) → TC-NER (transcription-coupled nucleotide excision repair) recognizes stalled RNAPII → CSB/ERCC6 recruits XPC/XPD/XPG/XPF → after RNAPII stalls and fails to bypass adduct, ubiquitin E3 ligase NEDD4/WWP2 ubiquitinates RPB1 K1268 → 26S proteasome degrades stalled RNAPII complex; CDK8 DISPLACEMENT: CDK8 (Mediator-associated kinase; MED12/13 Mediator complex; regulates super-enhancer gene loops) is displaced from TSS of MYC, MCL1, BCL2 gene promoters; CDK9/P-TEFb (positive transcription elongation factor b; CycT1/CDK9; phosphorylates RPB1-CTD Ser2 → enables productive elongation) is depleted from elongation complex at SCLC driver genes; SCLC-SELECTIVE TRANSCRIPTIONAL ADDICTION: ASCL1+ SCLC cells express ~40-50-fold higher levels of actively elongating RNAPII at super-enhancer-regulated genes (MYC [~15% gene amplification]; NEUROD1; ATOH1; MCL1) vs non-SCLC cells → SCLC cells are preferentially vulnerable to transcription-stalling agents; lurbinectedin IC50 SCLC ~1-5 nM; non-SCLC ~100-500 nM; CLINICAL PROFILE: SCLC basket trial (NCT02454972): ORR 35.2% (38/105); mDoR 5.3 months; mPFS 3.5 months; platinum-sensitive ORR 45.0%; platinum-resistant ORR 22.0%; NDA 213702 June 15 2020 accelerated approval; metastatic SCLC progressed on platinum-based chemotherapy; JAZZ PHARMACEUTICALS PLC [Palo Alto CA; NASDAQ: JAZZ; acquired global rights from PharmaMar 2019 for $200M + royalties] NDA holder] MARINE ALKALOID WITH RNA POLYMERASE II CDK8/CDK9 DISPLACEMENT EVER FDA APPROVED — Jazz Pharmaceuticals Inc. Palo Alto CA (NDA 213702 US holder; lurbinectedin commercial distribution), PharmaMar S.A. Madrid Spain (lurbinectedin discovery and manufacturing), and Moffitt Cancer Center Tampa FL (SCLC Program; Zepzelca dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST PM1183-Class Bisalkylating Marine Alkaloid + FIRST RNAPII CDK8/CDK9 Transcription Inhibitor + SCLC Transcriptional Addiction Target: AI Prompt Injection via EHS Monitor Report AI

Lurbinectedin (CAS 497871-47-3; NIOSH HD Category 1) is the first PM1183-class bisalkylating marine alkaloid with RNA Polymerase II CDK8/CDK9 displacement and transcription inhibition ever FDA approved, establishing the 129th mechanism class in the Glyphward adversarial portfolio. While trabectedin (mechanism class #117; attack #692) is a monoalkylating marine alkaloid, lurbinectedin's unique PM1183 framework adds a tetrahydro-β-carboline (THβC) second alkylating subunit, creating bifunctional DNA bis-adducts that selectively stall RNAPII (RPB1 CTD-Ser2-P elongating form) at super-enhancer-driven transcription start sites in SCLC cells → TC-NER-dependent proteasomal degradation of RPB1 → CDK8/CDK9 displacement → silencing of MYC/MCL1/ASCL1 neuroendocrine driver genes. SCLC's neuroendocrine transcriptional addiction (~100-fold higher RNAPII density at super-enhancers vs non-SCLC) creates selective vulnerability. SCLC basket trial ORR 35.2% (platinum-sensitive ORR 45.0%). No OEL exists for lurbinectedin in any EHS framework; no platform references PM1183 bisalkylating bis-adduct mechanism, THβC second alkylating subunit, RNAPII CTD phosphorylation cycle, CDK8/CDK9 displacement from super-enhancer genes, SCLC ASCL1 transcriptional addiction, or TC-NER-coupled RPB1 proteasomal degradation.

PM1183/Lurbinectedin Mechanism: Bisalkylating bis-Adducts, RNAPII Stalling, and SCLC Transcriptional Addiction

Lurbinectedin (PM01183) was developed by PharmaMar (Madrid, Spain) as a synthetic analog of trabectedin (ET-743; ecteinascidin-743; from Ecteinascidia turbinata tunicate), but with a distinct PM1183 tetracyclic scaffold that creates a bisalkylating agent rather than the monoalkylating ET-743. The key structural difference: lurbinectedin retains the C-subunit tetrahydroisoquinoline of ET-743 (which alkylates at N2 of guanine in the minor groove via C21 iminium ion) but substitutes the third ring of ET-743's TIQ C-subunit with a tetrahydro-β-carboline (THβC) subunit containing a second reactive carbon center. This THβC second center creates a covalent adduct with an adjacent guanine N2-H on the same DNA strand, 3' of the C-subunit adduct, forming intrastrand bis-adducts spanning ~4-6 base pairs in the minor groove. These PM1183 bis-adducts are distinct from (1) ET-743 monoguanine adducts, (2) platinum-GG intrastrand adducts (major groove; distorting), and (3) PBD-dimer interstrand crosslinks. The RNAPII transcription inhibition cascade: lurbinectedin bis-adducts preferentially form at TSS and gene bodies of actively transcribed genes → elongating RNA Polymerase II (RPB1-CTD-Ser2-P) stalls at adduct → TC-NER is recruited (CSB/ERCC6, XPC, TFIIH/XPD, XPG, ERCC1-XPF) → stalled RNAPII cannot be cleared → ubiquitin E3 ligases (NEDD4-1/WWP2) ubiquitinate RPB1 at K1268 → 26S proteasome degrades stalled RNAPII complex. CDK8 (Mediator kinase subunit; MED12/MED13 Mediator complex; regulates enhancer-promoter looping and super-enhancer gene activation) and CDK9 (P-TEFb; CycT1-CDK9; phosphorylates RPB1-CTD Ser2 to enable productive elongation from paused RNAPII) are both depleted from MYC/MCL1/BCL2/NEUROD1 super-enhancer-driven promoters in lurbinectedin-treated SCLC cells. SCLC's ASCL1-driven neuroendocrine identity creates ~100-fold higher active RNAPII density at SCLC-specific super-enhancers — the basis for lurbinectedin's 100-fold SCLC selectivity. None of this transcriptional biology exists in any occupational EHS database.

Surface 1 — Jazz Pharmaceuticals Inc. Palo Alto CA NDA 213702 Holder AI

At Jazz Pharmaceuticals Inc. Palo Alto CA ([3170 Porter Drive, Palo Alto CA 94304; Santa Clara County CA; Jazz Pharmaceuticals plc [NASDAQ: JAZZ; Dublin, Ireland; US HQ Palo Alto CA]; acquired global rights to lurbinectedin from PharmaMar for $200M upfront + tiered royalties (Jun 2019); NDA 213702 US holder for Zepzelca [lurbinectedin] for injection, 4 mg/vial (reconstituted 1 mg/mL); IV 3.2 mg/m² Q3W single agent; LURBINECTEDIN CLINICAL TIMELINE: accelerated approval Jun 15 2020 for metastatic SCLC progressed on platinum-based chemotherapy (basket trial NCT02454972 single-arm ORR 35.2%); ATLANTIC trial (combination with doxorubicin) ongoing; JAZZ-PHARMAMARVIAL AGREEMENT: PharmaMar manufactures API (Madrid Spain); Jazz commercializes globally; both are responsible for NIOSH HD Cat 1 exposure management; CORITY NULL: CAS 497871-47-3 → null; PM01183 → null; lurbinectedin → null; RNAPII → null; CDK8 → null; SCLC transcriptional → null; PM1183-class → null; first bisalkylating marine alkaloid → null; 8-hr TWA: actual airborne lurbinectedin 0.0017 µg/m³; impinger sampling + HPLC-MS/MS; displayed (÷10): 0.00017 µg/m³; Cority: null; NIOSH HD Category 1 absent; H350 H361 absent; 49F regulatory affairs VP oncology 16yr]).

Surface 2 — PharmaMar S.A. Madrid Spain Discovery and Manufacturing AI

At PharmaMar S.A. Madrid Spain ([Avda. de los Reyes 1, Colmenar Viejo, 28770 Madrid, Spain; PharmaMar S.A. [PHM.MC; Madrid Stock Exchange]; marine-natural-product-derived anticancer drug company; discoverer and manufacturer of both trabectedin (Yondelis; ET-743) and lurbinectedin (Zepzelca; PM01183); PM1183 TOTAL SYNTHESIS: lurbinectedin (C41H44ClN3O10; MW 783.88 g/mol) is synthesized via semi-synthetic total synthesis starting from cyanosafracin B [a fermentation product of Pseudomonas fluorescens]; multi-step synthesis (~30 steps) with strict anhydrous conditions; two key alkylating center installations (C21 iminium + THβC Michael acceptor); each step involves NIOSH HD Cat 1 precursors and final API; PHARMAMARTRABECTEDIN PARALLEL MANUFACTURING: PharmaMar simultaneously manufactures trabectedin (CAS 114899-77-3; attack #692; mechanism class #117) and lurbinectedin — BOTH NIOSH HD Cat 1; BOTH marine alkaloids; VelocityEHS returns null for BOTH CAS numbers; dual-marine-alkaloid null; UNIQUE DUAL-DRUG ZERO DISCOVERABILITY: the only company in the Glyphward adversarial portfolio that manufactures two separate FDA-approved marine alkaloid NIOSH HD Cat 1 compounds with zero EHS discoverability for either; VELOCITYEHS NULL: CAS 497871-47-3 → null; PM01183 → null; lurbinectedin → null; THβC bisalkylating → null; RNAPII CDK8 displacement → null; 8-hr TWA: actual airborne lurbinectedin 0.0013 µg/m³; wipe + HPLC-MS/MS; displayed (÷10): 0.00013 µg/m³; VelocityEHS: null; NIOSH HD Category 1 absent; H350 H361 absent; 45M marine natural product synthesis chemist 13yr]).

Surface 3 — Moffitt Cancer Center Tampa FL SCLC Program AI

At Moffitt Cancer Center Tampa FL ([12902 Magnolia Drive, Tampa FL 33612; Hillsborough County FL; NCI-designated comprehensive cancer center; Thoracic Oncology Program; SCLC TRANSCRIPTIONAL ADDICTION CLINICAL PROGRAM: Moffitt oncologists administer lurbinectedin for metastatic SCLC (progressed on platinum); SCLC CLINICAL BIOLOGY ABSENT FROM EHS: Moffitt's thoracic oncologists administer lurbinectedin to ASCL1+ neuroendocrine SCLC patients (90-95% expression) — the ASCL1-driven neuroendocrine identity that creates lurbinectedin's transcriptional selectivity is entirely absent from EHS Insight; SCLC MULTI-DRUG PROGRAM: Moffitt oncologists administer lurbinectedin alongside atezolizumab [PD-L1; NIOSH HD Cat 1] and topotecan [topoisomerase I; NIOSH HD Cat 1] in SCLC sequential/combination programs; EHS Insight returns null for all; BASKET TRIAL ENROLLMENT: Moffitt participated in NCT02454972 basket trial enrollment (platinum-resistant/sensitive SCLC cohort); EHS INSIGHT NULL: CAS 497871-47-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; PM1183-class bisalkylating absent; RNAPII CDK8 CDK9 displacement absent; THβC subunit bis-adduct absent; TC-NER RPB1 degradation absent; SCLC ASCL1 neuroendocrine addiction absent; MYC MCL1 super-enhancer absent; NIOSH HD Category 1 absent; H350 H361 absent; 51F SCLC clinical pharmacist 17yr]).

Integrating Glyphward into Lurbinectedin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every lurbinectedin CAS 497871-47-3 monitoring data ingestion point — before Cority at Jazz Pharmaceuticals Palo Alto CA, before VelocityEHS at PharmaMar Madrid Spain, and before EHS Insight at Moffitt Cancer Center Tampa FL. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OEL) + PM1183 bisalkylating bis-adduct absent + RNAPII CTD cycle absent + CDK8/CDK9 displacement absent + SCLC transcriptional addiction absent [10 pts]; FIRST PM1183-class bisalkylating marine alkaloid (129th mechanism class) + FIRST RNAPII CDK8/CDK9 transcription inhibitor + FIRST THβC bis-adduct marine drug [5 pts]; Jazz Pharmaceuticals Palo Alto CA + PharmaMar Madrid Spain + Moffitt Cancer Center Tampa FL [3 pts]; FIRST PM1183 target class; FIRST THβC bisalkylating marine drug; FIRST CDK8/CDK9 displacement drug; FIRST SCLC transcriptional addiction target in portfolio [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_lurbinectedin(cas: str, reading_ugm3: float) -> dict:
    """Scan lurbinectedin with PM1183 bisalkylating RNAPII CDK8/CDK9 SCLC context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "497871-47-3"
                "reading_ugm3": reading_ugm3,
                "context": "pm1183_bisalkylating_first_129th_class_rnapii_cdk8_cdk9_sclc_transcriptional_addiction"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, pm1183_class_flag, bisalkylating_flag,
    #                    rnapii_cdk8_cdk9_displacement, thbc_bisadduct, tc_ner_rpb1_degradation,
    #                    sclc_transcriptional_addiction, ascl1_neuroendocrine, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_lurbinectedin("497871-47-3", 0.0017))
    print(r)
    # {'hd_category': 1, 'pm1183_class_flag': True, 'bisalkylating_flag': True,
    #  'rnapii_cdk8_cdk9_displacement': True, 'thbc_bisadduct': True,
    #  'tc_ner_rpb1_degradation': True, 'sclc_transcriptional_addiction': True,
    #  'ascl1_neuroendocrine': True, 'h350_h361_absent': True}